Key result
Cicletanine increases endothelial nitric oxide and cGMP generation, suggesting a mechanism for its antihypertensive action.
Why the study?
The effects of cicletanine on human vascular endothelial cells regarding nitric oxide and related signaling pathways were not fully understood.
Does cicletanine affect nitric oxide and other signaling pathways in human umbilical vein endothelial cells?
Does cicletanine affect nitric oxide and other signaling pathways in human umbilical vein endothelial cells?
Cicletanine increases nitric oxide and cyclic GMP generation in human endothelial cells, suggesting a mechanism for its antihypertensive action.
Cicletanine's endothelial effects in vitro warrant human trials; leaves open any role in antihypertensive therapy.
The purpose of this study was to evaluate the effects of cicletanine, a slightly diuretic antihypertensive drug, on human vascular endothelial cells with regard to nitric oxide, intracellular calcium concentration ([Ca2+]i), cyclic nucleotide, inositol 1,4,5-trisphosphate (IP3), and prostacyclin generation. Primary cultured human umbilical vein endothelial cells were used in this study. [Ca2+]i was measured by fura-2/AM. Cyclic adenosine monophosphate (AMP), cyclic guanosine monophosphate (GMP), IP3, and prostacyclin were measured by radioimmunoassay. Nitric oxide was measured by the Griess method. Cicletanine had no effect on [Ca2+]i. Cicletanine (10(-6)-10(-4) M) increased cyclic GMP but decreased prostacyclin generation. Cicletanine had no stimulating effect on cyclic AMP or IP3 generation. IP3 increased 45Ca release from storage sites. Cicletanine decreased prostacyclin generation via increase in cyclic GMP. Cicletanine had no stimulating effect on nitrogen oxides for 2 h after incubation but increased it after 3-24 h. Pretreatment with L-N(G)-monomethyl-arginine (L-NMMA) prevented this increase. The inhibitory effect of L-NMMA was prevented by pretreatment with L-arginine. These results indicate that nitric oxide and cyclic GMP may contribute to the antihypertensive action of cicletanine.
No takes yet. Share an insight, caveat, or question.
Akamatsu et al. (2001) studied this question. Cicletanine was evaluated on Nitric oxide, intracellular calcium concentration, cyclic nucleotide, IP3, and prostacyclin generation. Cicletanine increased cyclic GMP and nitric oxide generation after 3-24 hours in human umbilical vein endothelial cells, suggesting these pathways contribute to its antihypertensive action.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: